Christian Parker | Associate Director

Christian Parker, Associate Director, Novartis

I grew up in Scotland and received my first degree from Edinburgh University. Then I moved to the University of Bristol, England, to gain a Ph.D. with Prof. Steve Halford, FRS, developing a novel method to monitor long range DNA/protein interactions. This work resulted in papers published in Cell and Nature. Following that I obtained a NATO post-doctoral award to study transposition at Yale University with Nigel Grindley. After this fellowship I joined Procter & Gamble, where I worked in the Skin Care and Pharmaceutical groups. In 1999, I joined the high throughput screening group of Pharmacia in Kalamazoo.  While in Kalamazoo I helped Dr. Brian Tripp of Western Michigan University to set up a Master’s degree course in High Throughput Screening. In 2003, I left Pharmacia to join the Lead Discovery Group of Novartis in Cambridge, MA., and in 2005 transferred to the Cell Based Screening group in Basel, Switzerland. At the end of 2009 I had the opportunity to set up a high throughput biology laboratory supporting target discovery projects. The group has developed from screening predominantly siRNAs and cDNAs to include pooled CRISPR approaches. My research group is involved with the development, optimization, validation, automation and data analysis of high throughput screens.  These are conducted for a number of different therapeutic areas including: anti-infectives, autoimmunity and transplantation, CNS, respiratory, metabolic and cardiovascular disease areas. During my industrial career I have worked with a number of different post-doctoral student developing novel informatics methods and biology projects. These projects have resulted in papers in journals such as JBC, J. Med. Chem., JACS, Antimicrob. Agents & Chemother., ChemBiochem., Bioorg & Med Chem Letts., J. Chem. Inf. Comput. Sci., J. Biomol. Screen and Assay Drug Dev. Technol. As well as reviewing manuscripts for a number of journals including J. Med. Chem. and Nature Biotechnology, I also served as Associate Editor for SLAS Discovery. Between 2007 and 2011. I was involved with the organization of the drug discovery conference MipTec; first as co-Chair of the Poster Session, I then took on the role as co-chair of the program committee and secretary to the session committee. During this time MipTec went from being a very small conference focusing on microtitre plate technologies, to being the largest drug discovery conference in Europe. In 2016 I was elected to the SLAS European Council for a three year appointment. Then in 2021, I accepted the role as a European Ambassador for SLAS as part of this role we have initiated regular virtual meet-ups to increase member engagement, as well as, face to face meetings when possible.


Day 2 (27th June) @ 13:29


Day 2 (27th June) @ 14:44


Day 2 (27th June) @ 15:15

Closing panel: Exploring innovative and transformative technologies in drug discovery and beyond

Developed in collaboration with ELRIG

last published: 17/Jun/24 14:15 GMT

back to speakers



For conference production and speaking opportunites:

Für die Produktion von Konferenzen und die Möglichkeit, Vorträge zu halten: 

For sponsorship and exhibition opportunities: